No Mortality Advantage for Higher-Dose Steroids in Pneumonia

This network meta-analysis clarifies that once corticosteroids are given for community-acquired pneumonia, escalating the dose does not measurably lower short-term mortality.

corticosteroidsdexamethasonecommunity-acquired pneumoniaCAPnetwork meta-analysiscritical caresepsismortalitydose comparison Critical Care / ICU

Background Information

Lower and higher corticosteroid doses both reduce pneumonia mortality.

Corticosteroids are used to improve outcomes in patients hospitalized with community-acquired pneumonia (CAP), but optimal dosing is unclear. Both higher-dose and lower-dose corticosteroids reduced short-term mortality compared to placebo: higher-dose risk ratio (RR) 0.83 and lower-dose RR 0.84. No significant difference was found between doses. The study suggests lower-dose corticosteroids may be sufficient for CAP, as no significant mortality difference was found compared to higher doses. Results are limited by low confidence in dose comparisons. Both lower and higher doses of corticosteroids reduce short-term mortality in CAP with no clear advantage between dosing regimens.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ouyang Y, Lai J, Wang P, Yuan X, Wang H, Xiang Z, Xiao Y, He J, Wan J, Fang F, Zhang Y, Jia L

Citation: Ouyang Y, Lai J, Wang P, et al. Efficacy of higher-dose versus lower-dose corticosteroids in community-acquired pneumonia: a systematic review and network meta-analysis. Critical care (London, England). 2026. doi:10.1186/s13054-026-06185-5

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →